Selected article for: "emergency department and stay ICU length"
Author: Melton, James D.; Wilson, Kayla; Blind, Fred; Barbera, Andrew; Bhisitkul, Donna; Hasara, Shannon; Homa, Karen; Karp, Juliana; Escowitz, Hal; Haber, Todd; DeGroot, Diana; Anderson, Jonathan; DeLeon, Jason; Santos, Jesse De Los; Faviere, Donna; Fuell, Joanne; Gillespie, Rita; Glueck, Jesse; Reeber, Cliff; Rhodes, David; Rodriguez, Vashun
Title: Impact of early versus late administration of bamlanivimab on readmissions in patients with high-risk COVID-19
  • Cord-id: t9itaglb
  • Document date: 2021_8_16
    • ID: t9itaglb
    Snippet: BACKGROUND: Recombinant, monoclonal antibody therapies have been utilized under emergency use authorization (EUA) for the prevention of clinical decompensation in high-risk COVID-19 positive patients for up to 10 days from symptom onset. The purpose of this study was to determine the impact of the timing of the monoclonal antibody, bamlanivimab, on clinical outcomes in high-risk COVID-19 positive patients. METHODS: This was an IRB-approved, retrospective evaluation of adult patients who received
    Document: BACKGROUND: Recombinant, monoclonal antibody therapies have been utilized under emergency use authorization (EUA) for the prevention of clinical decompensation in high-risk COVID-19 positive patients for up to 10 days from symptom onset. The purpose of this study was to determine the impact of the timing of the monoclonal antibody, bamlanivimab, on clinical outcomes in high-risk COVID-19 positive patients. METHODS: This was an IRB-approved, retrospective evaluation of adult patients who received bamlanivimab per EUA criteria in the emergency department (ED). Patients were dichotomized into two groups– 3 days of symptoms or less (early) versus 4 to 10 days (late). The primary outcome was hospitalization for COVID-related illness at 28 days (or treatment failure). Secondary outcomes were COVID-related ED visits at 28 days, hospital and intensive care unit (ICU) length of stay (LOS), and in-hospital mortality at 28 days. RESULTS: A total of 839 patients were included in the analysis. There was no difference observed in COVID-related hospitalization rates within 28 days between the early and late bamlanivimab administration groups (7.5% vs. 8.2%, p = 0.71). There was no difference in COVID-related ED visits within 28 days with 13% of patients returning to the ED. CONCLUSIONS: In conclusion, there were no differences in the rates of hospitalization at 28 days when bamlanivimab was administered in the first 3 days of illness versus days 4 to 10. Future prospective studies are warranted to expand upon the characteristics of patients that may or may not benefit from monoclonal antibody therapy.

    Search related documents:
    Co phrase search for related documents
    • admission require and logistic model: 1, 2, 3, 4, 5, 6
    • admission require and logistic regression analysis: 1, 2, 3, 4, 5, 6, 7, 8
    • admission require and los stay length: 1, 2, 3
    • admission require and low certainty: 1
    • admission require and low incidence: 1
    • admission require likely and logistic analysis: 1, 2
    • admission require likely and logistic model: 1, 2
    • admission require likely and logistic regression analysis: 1, 2
    • admission require likely and los stay length: 1
    • admission require likely and low certainty: 1
    • logistic analysis and los stay length: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13
    • logistic analysis and low certainty: 1
    • logistic analysis and low incidence: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11
    • logistic model and los stay length: 1, 2, 3, 4, 5, 6, 7, 8
    • logistic model and low certainty: 1, 2
    • logistic model and low incidence: 1, 2, 3
    • logistic model variable and los stay length: 1
    • logistic regression analysis and low certainty: 1
    • logistic regression analysis and low incidence: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11